Neoadjuvant rectal (NAR) score may serve as a surrogate short‐term endpoint for overall survival (OS) in clinical trials. This study aims to test the NAR score using a large, national… Click to show full abstract
Neoadjuvant rectal (NAR) score may serve as a surrogate short‐term endpoint for overall survival (OS) in clinical trials. This study aims to test the NAR score using a large, national cancer registry.
               
Click one of the above tabs to view related content.